RENBP and metabolic dysfunction-associated steatotic liver disease: The KEGG analysis indicated that KD treated metabolic syndrome by regulating certain signaling pathways including AGE-RAGE signaling pathway in diabetic complications (hsa04933), TNF signaling pathway (hsa04668), adipocytokine signaling pathway (hsa04920), insulin resistance (hsa04931) and non-alcoholic fatty liver disease (hsa04932).